Noruega - norueguês - Statens legemiddelverk

abacus medicine a/s - venetoklaks - tablett, filmdrasjert - 50 mg

Noruega - norueguês - Statens legemiddelverk

abacus medicine a/s - venetoklaks - tablett, filmdrasjert - 100 mg

Noruega - norueguês - Statens legemiddelverk

accord healthcare b.v. - valganciklovirhydroklorid - tablett, filmdrasjert - 450 mg

Noruega - norueguês - Statens legemiddelverk

orifarm as - ponatinibhydroklorid - tablett, filmdrasjert - 15 mg

Noruega - norueguês - Statens legemiddelverk

medical valley invest ab - valganciklovirhydroklorid - tablett, filmdrasjert - 450 mg

Noruega - norueguês - Statens legemiddelverk

cheplapharm arzneimittel gmbh - valganciklovirhydroklorid - tablett, filmdrasjert - 450 mg

Noruega - norueguês - Statens legemiddelverk

sandoz - københavn - valganciklovirhydroklorid - tablett, filmdrasjert - 450 mg

Noruega - norueguês - Statens legemiddelverk

cheplapharm arzneimittel gmbh - valganciklovirhydroklorid - pulver til mikstur, oppløsning - 50 mg/ ml

União Europeia - norueguês - EMA (European Medicines Agency)

pharmaand gmbh - rucaparib camsylate - ovarie neoplasmer - antineoplastiske midler - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca er indisert som monoterapi for vedlikehold behandling av voksne pasienter med platinum-sensitive tilbakefall av høy klasse epithelial ovarian, egglederen, eller primær-peritoneal kreft som er i respons (hel eller delvis) til platinum-basert kjemoterapi.

União Europeia - norueguês - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se avsnitt 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.